Skip to main content

Table 2 Correlation between clinical pathologic characteristics and AGLR level in HCC patients

From: AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study

Variables

AGLR level

Training cohort (n = 248)

Validation cohort (n = 247)

 ≤ 90 n (%)

 > 90 n (%)

p value

 ≤ 90 n (%)

 > 90 n (%)

p value

Age (years)

 ≤ 60

92 (46.2)

107 (53.8)

0.347

81 (41.3)

115 (58.7)

0.815

 > 60

19 (38.8)

30 (61.2)

 

22 (43.1)

29 (56.9)

 

Gender

      

 Female

18 (60.0)

12 (40.0)

0.073

18 (52.9)

16 (47.1)

0.152

 Male

93 (42.7)

125 (57.3)

 

85 (39.9)

128 (60.1)

 

Drinking

      

 No

62 (44.6)

77 (55.4)

0.958

58 (43.3)

76 (56.7)

0.583

 Yes

49 (45.0)

60 (55.0)

 

45 (39.8)

68 (60.2)

 

HBsAg

      

 Negative

14 (38.9)

22 (61.1)

0.444

17 (43.6)

22 (56.4)

0.794

 Positive

97 (45.8)

115 (54.2)

 

86 (41.3)

122 (58.7)

 

AFP (ng/mL)

      

 ≤ 20

54 (62.8)

32 (37.2)

 < 0.001

43 (58.6)

30 (41.4)

 < 0.001

 > 20

57 (35.2)

105 (64.8)

 

60 (34.5)

114 (65.5)

 

Liver cirrhosis

      

 No

8 (57.1)

6 (42.9)

0.337

10 (43.5)

13 (56.5)

0.856

 Yes

103 (44.0)

131 (56.0)

 

93 (41.5)

131 (58.5)

 

Tumor size (cm)

      

 ≤ 5

66 (65.3)

35 (34.7)

 < 0.001

61 (56.5)

47 (43.5)

 < 0.001

 > 5

45 (30.6)

102 (69.4)

 

42 (30.2)

97 (69.8)

 

Tumor number

      

 Single

90 (48.6)

95 (51.4)

0.035

84 (43.5)

109 (56.5)

0.272

 Multiple

21 (33.3)

42 (66.7)

 

19 (35.2)

35 (64.8)

 

TNM stage

      

 I-II

82 (68.9)

37 (31.1)

 < 0.001

81 (57.4)

60 (42.6)

 < 0.001

 III- IV

29 (22.5)

100 (77.5)

 

22 (20.8)

84 (79.2)

 

Microvascular invasion

      

 No

95 (52.2)

87 (47.8)

 < 0.001

96 (46.2)

112 (53.8)

0.001

 Yes

16 (24.2)

50 (75.8)

 

7 (17.9)

32 (82.1)

 

Recurrence

      

 No

70 (47.0)

79 (53.0)

0.388

71 (45.2)

86 (54.8)

0.138

 Yes

41 (41.4)

58 (58.6)

 

32 (35.6)

58 (64.4)

 
  1. AGLR, alkaline phosphatase plus gamma-glutamyl transpeptidase to lymphocyte ratio; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis